Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

References

• Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res. 1998;72; 197–233
   Google Scholar
• Cros E, Jordheim L, Dumontet C, Galmarini C M. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1123–1132
   PubMed Web of Science ®Google Scholar
• Fernandez-Calotti P, Jordheim L P, Giordano M, Dumontet C, Galmarini C M. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma 2004; 46: 335–346
   Web of Science ®Google Scholar
• Frewin R J, Johnson S A. The role of purine analogue combinations in the management of acute leukemias. Hematol Oncol 2001; 19: 151–157
   PubMed Web of Science ®Google Scholar
• Hubeek I, Peters G J, Broekhuizen A JF, Sargent J, Gibson B ES, Creutzig U, et al. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol 2005; 131: 219–222
   PubMed Web of Science ®Google Scholar
• Hubeek I, Peters G J, Broekhuizen A JF, Kaspers G JL. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1513–1516
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Korycka A, Robak T. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro. Haematologica 2000; 85: 588–594
   PubMed Web of Science ®Google Scholar
• Bergman A M, Kuiper C M, Myhren F, Sandvold M L, Hendriks H R, Peters G J. Anti proliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1523–1526
   PubMed Web of Science ®Google Scholar
• Bergman A M, Kuiper C M, Voorn D A, Comijn E M, Myhren F, Sandvold M L, et al. Anti proliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004; 67: 503–511
   PubMed Web of Science ®Google Scholar
• Breistol K, Balzarini J, Sandvold M L, Myhren F, Martinsen M, De Clercq E, et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 1999; 59: 2944–2949
   PubMed Web of Science ®Google Scholar
• Aamdal S, Dueland S, Lind M J, Thomas H, Franks C R, Sandvold M L, et al. Phase I trial of a nucleoside analog CP-4055 given daily for 5 days every 3 weeks in patients (pts) with advanced solid tumours – preliminary results. J Clin Oncol 2004; 22: 139S–139S
   Google Scholar
• Delaunoit T, Raymond E, Awada A, Savinelli F, Culine S, Rasch W, et al. A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumours. J Clin Oncol 2006; 24: 95S–95S
   Google Scholar
• Giles F, Rizzieri D, Prebet T, Charbonnier A, Jacobsen T, Hernes K, et al. CP-4055 in Patients with Haematologic Malignancies: A Phase I Study. AACR, Los Angeles, CA 2007
   Google Scholar
• Collins S J, Gallo R C, Gallagher R E. Continuous growth and differentiation of human myeloid leukemic-cells in suspension culture. Nature 1977; 270: 347–349
   PubMed Web of Science ®Google Scholar
• Liu T X, Becker M W, Jelinek J, Wu W S, Deng M, Mikhalkevich N, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78–83
   PubMed Web of Science ®Google Scholar
• Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565–577
   PubMed Web of Science ®Google Scholar
• Shanks R H, Rizzieri D A, Flowers J L, Colvin O M, Adams D J. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res 2005; 11: 4225–4233
   PubMed Web of Science ®Google Scholar
• Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55
   PubMedGoogle Scholar
• Chou T C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681
   PubMed Web of Science ®Google Scholar
• Kanzawa F, Nishio K, Fukuoka K, Fukuda M, Kunimoto T, Saijo N. Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int J Cancer 1997; 71: 311–319
   PubMed Web of Science ®Google Scholar
• Prichard M N, Shipman C. A 3-dimensional model to analyze drug-drug interactions. Antiviral Res 1990; 14: 181–206
   PubMed Web of Science ®Google Scholar
• Minderman H, O'Loughlin K L, Smith P F, Pendyala L, Greco W R, Sweeney K G, et al. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemother Pharmacol 2006; 57: 73–83
   PubMed Web of Science ®Google Scholar
• Giles F J, Cortes J E, Kantarjian H M, O'Brien S M, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res 2004; 28: 353–357
   PubMed Web of Science ®Google Scholar
• Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel L W, et al. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002; 8: 2499–2504
   PubMed Web of Science ®Google Scholar
• Giles F J, O'Brien S, Vey N, Feldman E, Rizzieri D, Khan K D, et al. Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MIDS). J Clin Oncol 2005; 23: 570S–570S
   Google Scholar
• Penketh P G, Shyam K, Baumann R P, Remack J S, Brent T P, Sartorelli A C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydra zine (VNP40101M). I. Direct inhibition of O-6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 2004; 53: 279–287
   PubMed Web of Science ®Google Scholar
• Adams D J. In vitro pharmacodynamic assay for cancer drug development – application to crisnatol, a new DNA intercalator. Cancer Res 1989; 49: 6615–6620
   PubMed Web of Science ®Google Scholar
• Adema A D, Zuurbier L, Floor K, Hubeek I, Kaspers G JL, Albertoni F, et al. Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells. Nucleosides Nucleotides Nucleic Acids 2006; 25: 981–986
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Keating M, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 1993; 10(Suppl)109–114
   PubMedGoogle Scholar
• Gandhi V, Estey E, Keating M J, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Mayer L D, Harasym T O, Tardi P G, Harasym N L, Shew C R, Johnstone S A, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Therapeutics 2006; 5: 1854–1863
   PubMed Web of Science ®Google Scholar